Vaxcyte, Inc. Net Income Loss

Quick Answer

Vaxcyte, Inc. reported Net Income Loss of -$766.63 million for the year ending 2025.

  • Vaxcyte, Inc. showed a decrease of -65.2% in Net Income Loss from 2024 to 2025.
  • This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Vaxcyte, Inc.'s Net Income Loss has declined by 2,500.1%.
  • Historical annual values: Fiscal year 2025: -$766.63 million | Fiscal year 2024: -$463.93 million | Fiscal year 2023: -$402.27 million | Fiscal year 2022: -$223.49 million | Fiscal year 2021: -$100.08 million | Fiscal year 2020: -$89.22 million | Fiscal year 2019: -$50.27 million | Fiscal year 2018: -$29.49 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: